PRMT5 and systemic sclerosis: Furthermore, using the 99th percentile as the upper limit of normal, anti-PRMT5 antibodies were present in 31.11% of patients with SSc (28/90) and absent in HC (0/84) (figure 3B), with sensitivity, specificity, positive predictive value and negative predictive value of 70.24%, 97.78%, 96.72% and 77.88%, respectively.